Glaxosmithkline Share News (GSK)

Winter is coming... and so are earnings downgrades

STOXX 600 falls 0.5%

*

Being bearish but also bullish on Europe Inc

STOXX 600 down 0.5%

*

Forza Italia in early Europe

STOXX 600 down 0.2%

*

LONDON MARKET OPEN: Pharmaceutical stocks led by GSK spare FTSE 100

(Alliance News) - Stock prices in London mostly opened flat on Wednesday, with falls in FTSE 100 housebuilders, miners and oil majors offset by gains for pharmaceuticals as GSK shook off Zantac litigation.

Sanofi shares rally as company avoids U.S. lawsuits over Zantac

PARIS, Dec 7 (Reuters) - Sanofi shares rose by around 8% in early Paris stockmarket trading on Wednesday after the company avoided thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer.

LONDON BRIEFING: Stocks called flat on mixed news from China

(Alliance News) - Stocks in London were set to start flat on Wednesday, as weak economic data from China pointed to a "deep malaise" in the global economy, though this was offset by news that Asia's largest economy will loosen its strict zero-Covid measures.

GSK shares jump as court dismisses ranitidine claims

(Sharecast News) - GSK shares were surging on Wednesday morning, as it welcomed a ruling by the multi-district litigation court (MDL) over the heartburn drug ranitidine on Wednesday.

GSK, Pfizer, Sanofi fend off thousands of U.S. lawsuits over alleged Zantac cancer link

Dec 6 (Reuters) - Drugmakers GSK Plc, Pfizer Inc , Sanofi SA and Boehringer Ingelheim on Tuesday were spared thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science.

TOP NEWS: GSK welcomes Zantac legal boost in Florida

(Alliance News) - GSK PLC on Tuesday welcomed a US verdict in a lawsuit which had claimed the Zantac heartburn drug caused cancer.

GSK, Pfizer, Sanofi escape U.S. federal litigation over Zantac

Dec 6 (Reuters) - Drugmakers GSK Plc, Pfizer Inc , Sanofi SA and Boehringer Ingelheim on Tuesday defeated thousands of lawsuits in U.S. federal court claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science.

LONDON BROKER RATINGS: Jefferies cuts Persimmon; BoA cuts GSK

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

LONDON BROKER RATINGS: Jefferies raises AJ Bell to 'buy' from 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

LONDON MARKET OPEN: Stocks mixed with eyes on US data; dollar weaker

(Alliance News) - Stocks in London were mixed at the open on Friday ahead of the release of a key gauge of US economic health, the non-farm payrolls report, which many expect to influence the size of the Federal Reserve's next interest rate hike at its next meeting this month.

TOP NEWS: GSK gets EMA validation for bone marrow cancer treatment

(Alliance News) - GSK PLC on Friday said the European Medicines Agency has accepted a marketing authorisation application for momelotinib, its treatment for myelofibrosis, a rare bone marrow cancer. Additionally, it announced positive results from a trial investigating Jemperli.

LONDON BRIEFING: Asos interim CFO departs; Safestore enters Germany

(Alliance News) - Stocks in London are set to open marginally lower on Friday, ahead of US non-farm payrolls later in the day, a piece of data expected to loom large for the US Federal Reserve at its December meeting.